Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
At what point would TEVA start to get interesting even with the threat of generic copaxone and no Teva Lovenox? At $40? At $35? Sure I would like to see it go really low as punishment for the headaches they have caused to MNTA investors. But at some point TEVA has got to look be a bargain, right? Thanks.
Anybody listening to the Teva conference call? Any questions on Teva-Lovenox or threat of generic Copaxone?
Thanks.
7.9 Million shares still short. 18 days to cover based on the recent average daily volume,
http://www.nasdaq.com/aspxcontent/shortinterests.aspx?symbol=MNTA&selected=MNTA
Tekcor, instead of a large seller liquidating, couldn't it be a hedge fund shorting at around the 19.50 or the 19.20 mark all day? Couldn't this be a possibility? Thanks.
That would be nice if it were true. But it would mean price manipulation to benefit the big institutions. I guess that is nothing new
If it were true then the float would also be reduced, making the short squeeze if and when it happens that much more explosive.
However, I think it is the shorts adding to their positions all day.
All in all a very frustrating day! I just feel cheated today.
I think it is the short sellers shorting a lot more today at that level. It would be interesting to see if we can find that information at the end of the day.
There was a 60 minutes episode about 7-8 months ago about a very few select people who remember everything they had done every day of their life. They could recollect what they were doing say on Oct 16th 1983 or Sep 15th 1977 and what they had for dinner etc.
I am guessing Dew is like one of these amazing people
All I can say is I am extremely glad to have found Biotech Values and MNTA and the incomparable Dew! He certainly has helped me make some money.
Thanks Dew, for everything you do!
So, using last quarters numbers from
http://finance.yahoo.com/q/is?s=MNTA
284 * .6816 (margin) * .45 (profit share) = 87.1 revenue
Assuming same expenses as last quarter = 21.1 gives us 66 mil profit.
Using the same 50.45m shares used in the last quarter calculation (57.006 / 50.45 = $1.13)
That would mean 66 / 50.45 = $1.31 earnings.
Even if expenses increased to about 24 million, we would still have about 63 / 50.45 = $1.25
Does this seem right to you guys?
Probably the ones who worked on the Teva-Lovenox program
Hmm! I am no expert. I have been trading options for about 4 months and I have made a lot of money in it buying calls.
One of the first biotech options I bought was the May 2011 CSLN $2.5 call when it was trading around 2.3. I only paid 0.10 cents for it. 10 days later that option was at 0.90 cents. (the stock shot up to $3.4). I sold it for 0.60 - 0.70 cents. Didn't quite get the peak. But still a 6-7 bagger in 10 days is nice Thanks goes to Patrick Crutch who first brought CSLN to this or the FDA plays board's attention saying how undervalued it was
I got a bunch of MNTA Sep $10 calls at $5.3 in March/April when MNTA was in the $13-14 range. I started selling them off between $10-11 last week when MNTA was between $20-21. I also had a lot of out of the money September calls that have at least tripled in value.
I bought the CLSN Jan 2012 $5 call at 0.35 cents a month ago when CLSN was under 3. I started selling them between 0.95 and 1.05 (a triple in a month) when CLSN went over $4.
I have also made money in MITI calls which I purchased when MITI dipped below $5.4 a few months ago. I was working of the list jq1234 had provided a few months back; Thanks jq!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=61581821
Sure, I have had a few biotech calls go against me like CLDX, ARRY, CBLI & BMTI. Although, I am hoping that if CLDX goes over $4.2 by August 20th, I will not have to take a loss in that. With CBLI and BMTI I lost the entire amount.
In non-biotech, I have had some nice winners. I got the BPI Nov $30 call at around $0.4 cents while BPI was trading under $20. These calls were priced at around $2.5 on Friday. Unfortunately I had sold everything around $2.0 . I also had the GLUU (purchased as a Zynga IPO-hype play) Dec $5 call between 0.30 to 0.40 cents a couple of months ago. This was priced at $1.6 on Friday.
If you had bought the Aug GOOG $550 call for around $11 on Thursday, you would have made 400% in a day. You could have sold it for around $50 on Friday. I thought about it, but didn't buy it
With calls, even if you are 50-50, the winners should more than make up for the losers.
Now, if there is a Teva Lovenox, I might never play options again. I hope that doesn't happen
Yes, I started first with selling covered calls (DCTH where you get decent premiums on the spikes up) and writing puts (MNTA). DCTH is almost $2 lower than when I purchased it, but the covered call premiums have more than made up for that difference. MNTA puts have always been very profitable yielding 10% or more for 2-3 months. I never once ended being put the stock (I have enough of that already!)
Finally, I have VXX calls or TZA or TYP calls as a hedge if Cantor, Boehner and the other bozos in Washington don't resolve the debt ceiling issue.
My bad! I saw CLDX in the list of messages and I thought he was referring to that.
I am long CLSN since 2.35 long CSLN Jan $5 calls from 0.35 cents
It has a high of $3.75 today. When did you sell at $4? Was it sometime back? Thanks. I still have some calls that I purchased at $4 before they did their financing. I am hoping to get out even soon.
How confident are you that it will reach 527?
I will only feel comfortable if it crosses 20.75 (20.70 was the June 8th high) on really high volume (1 million+). Then we can be sure that some shorts have started covering.
http://finance.yahoo.com/q/hp?s=MNTA+Historical+Prices
What's with the after hours trading? It is down exactly $1. Not a lot, about 2,000 shares at $18.90.
http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx?selected=MNTA&mkttype=after
Don't worry about it, I understand it fully. I have made over 19k in profits in MNTA calls and over 6K in profits in written puts on MNTA alone since March.
I just expressed a concern that MNTA Jan 2013 $20 calls would lose half its current value if there was a takeover bid at $22.5 (it could happen if you believe the analysts who say T-Enox will come to market in 2H 2011 and the stock price could lose half its value -- in which case a takeover bid for $22.5 is not out of the question because of future revenues from M-Copaxone).
I just was curious if people think of the takeover possibility when buying LEAPS. It may make sense to buy a $35 or even $40 MNTA 2014 call (when it becomes available) because by then the possibility of FDA approval of M-Copaxone is very high. So the $35-$40 stock price is not far fetched. However, if the company is bought any time before that for a lower price then the options are worthless.
Problem with Call Options:
I was in an unique situation where a stock was up $2.2 but my now in-the-money option was down $1.2 yesterday. This happened with my Jan 2012 $50 BJ's Wholesale call. On Tuesday the stock was at $48.1 and the $50 call was at $2.45. Yesterday BJ's agreed to be bought at $51.25 so the option value dropped to $1.25 and the stock went up $2.2 to $50.3 (I am not sure why it didn't end up at around $51.25). Luckily, I only paid $1.5 for the option so I have a small loss. I am hoping the share holders reject this offer as it is only a 7% premium. On Tuesday Goldman had said that the stock is worth $60.
http://finance.yahoo.com/q/op?s=BJ&m=2012-01
Now, hopefully this won't happen with MNTA with an offer price of $22.5 or so (hostile takeover attempt). Then the MNTA $20 Jan 2013 call (at around $5.2) would immediately drop to $2.5. I used this example because I own a lot of these calls (purchased while MNTA was in the $15-$18 range). Obviously the $25, $30, $35 call values will all drop to $0 then.
http://finance.yahoo.com/q/op?s=MNTA&m=2013-01
I am curious to know if people consider this possibility while buying options.
Thanks.
B of A / Merrill starts coverage for LinkedIn with a Buy and price target of $92 while they start coverage for Momenta with an underperform and price target of $19. I hate these crooked bas***ds!
Moron ANALyst at B of A / Merrill initiates coverage with an underperform and target of $19. Teckcor, there goes the countdown Looks like there is a concerted effort to keep the price down.
On the contrary. It increased just a little to 8.9 m shares. All these will hopefully be rushing to buy this stock soon
http://shortsqueeze.com/?symbol=MNTA&submit=Short+Quote%99
No, not usually. However, in this case Jbog had indicated that he was in this for a trade.
All the analysts on twitter at that time (Adam, and Gekko and possibly Jason) and Patrick and a bunch of others were discussing how ONTY's run up was unjustified (from 3 to 9 on no news). That was when a bunch of people including the Biorunup guy (who possibly has hundreds of subscribers following his moves) decided to buy puts or short. It would not have been a big deal if it just was one or two people. So, in this case I felt it was wise to caution jbog since he was merely in it for a trade.
Jbog, be careful. Everybody on twitter bought PUTS (not me, I have no position) today. There was a discussion on why this kept running up and then a lot of them decided to short / buy puts. That is when it collapsed.
http://twitter.com/#!/search/%24ONTY
Tekcor, is everything good technically with MNTA if it finishes above 18.5 on good volume today?
I would appreciate your TA.
Thanks.
Generic of Teva's Copaxone likely years away, says Wells Fargo (From the FlyOnTheWall.com)
Wells Fargo believes the U.S. District Court's denial of Teva's (TEVA) request for a summary judgment in the Copaxone patent infringement suit against Mylan (MYL) does not offer a read on the final outcome of the trial. The firm continues to think a generic version of Copaxone is years away and maintains an Outperform rating on Teva shares.
This idiot analyst's comment could weigh on MNTA today.
A U.S. court on Friday denied a motion by Teva Pharmaceutical Industries (TEVA.TA) for summary judgment in the Copaxone patent infringement lawsuit it has brought against Mylan Inc
http://www.reuters.com/article/2011/06/17/mylan-teva-idUSN1728129820110617?feedType=RSS&feedName=marketsNews&rpc=43
Is anybody going to be posting updates from tomorrow's annual meeting? It would be greatly appreciated! Thanks.
Wow! If we get M-Copaxone approval any time soon, I can retire Just need to figure out what do with medical insurance
I shouldn't get my hopes up too high. I thought today would surely be the day we smashed the 20.25 resistance only for it to fall back to 19.10.
Finally, we have an ANALyst willing to take some sort of a stand backing MNTA
http://www.theflyonthewall.com/permalinks/entry.php/
Momenta Pharma may benefit from FDA's Copaxone statements, says Oppenheimer
After the FDA said that clinical trials wouldn't necessarily be an approval requirement for generic versions of Teva's (TEVA) Copaxone and added that it can determine whether generic versions of Copaxone are identical enough to the actual drug, Oppenheimer believes these statements have positive implications for Momenta, which has developed a generic version of Copaxone. The firm maintains an Outperform rating on Momenta
Finally, we have an ANALyst willing to take some sort of a stand backing MNTA
http://www.theflyonthewall.com/permalinks/entry.php/
Momenta Pharma may benefit from FDA's Copaxone statements, says Oppenheimer
After the FDA said that clinical trials wouldn't necessarily be an approval requirement for generic versions of Teva's (TEVA) Copaxone and added that it can determine whether generic versions of Copaxone are identical enough to the actual drug, Oppenheimer believes these statements have positive implications for Momenta, which has developed a generic version of Copaxone. The firm maintains an Outperform rating on Momenta
How can TEVA lie this blatantly?
The US Food and Drug Administration (FDA) has postponed a ruling on the Citizens Petition of Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA; TASE:TEVA) to prevent the launching of generic Copaxone. A company spokesman told "Globes" that the FDA decision has been put off to an unspecified date.
Teva was responding to a report on "Fly on the Wall" yesterday that the FDA had dismissed the company's petition regarding Copaxone, Teva's flagship multiple sclerosis treatment.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000652722&fid=1725
Dew, what does this mean to MNTA's chances of getting M-Copaxone approval in 2011? Thanks.
Patrick, write an article in Seeking Alpha suggesting that NVS is looking to buy MNTA. That should kill the shorts and give us the liftoff that Tekcor has been suggesting will happen soon . Also, please don't post it under Michael Garza's name because we don't want MNTA to be associated with Garza
Just kidding
Long MNTA since February. (My biggest holding by far)
What price spikes? Were you by any chance using Options Express Xtend software? I noticed a glitch here in the software.